Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 1015550

Drug Profile

BI 1015550

Alternative Names: BI1015550

Latest Information Update: 04 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antifibrotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 10 Jul 2019 Boehringer Ingelheim completes a phase I trial in Idiopathic pulmonary fibrosis in United Kingdom, Italy, Germany, Denmark, Belgium, Finland, Netherlands and Spain (PO) (NCT03422068)
  • 13 Aug 2018 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT03403439) (EudraCT2017-003452-23)
  • 04 Jun 2018 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Japan in June 2018 (NCT03542344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top